desvenlafaxine extended release / Generic mfg. - LARVOL DELTA

Adjustment for dispensed doses does not explain higher antidepressant concentrations in post-mortem toxicology. (PubMed, Br J Clin Pharmacol) - "Dose adjustment generally did not improve the separation of poisoning vs non-poisoning suicides, indicating that post-mortem concentrations may not have clear dose-concentration relationships."

Journal

Low-dose intravenous esketamine on a depressive catatonia patient with venous thromboembolism: a case report. (PubMed, Front Psychiatry) - "Benzodiazepines, aripiprazole and nutritional support were given after admission...With the consent of her and family, we decied to administrate a sub-anesthetic dose of intravenous (IV) Esketamine (0.2 mg/Kg) combined with 50mg desvenlafaxine...As a safe and rapid intervention, Esketamine might be a new option for catatonic patients who cannot undergo MECT or fail to respond to conventional treatment. It may be worthy of further research in the future."

Journal • Anesthesia • Cardiovascular • CNS Disorders • Depression • Hematological Disorders • Major Depressive Disorder • Mood Disorders • Psychiatry • Thrombosis • Venous Thromboembolism

Efficacy and safety of Toludesvenlafaxine extended-release tablets in the treatment of treatment-resistant depression. (PubMed, BMC Psychiatry) - P4 | "These findings suggest that Toludesvenlafaxine may be associated with improvements in both depressive and anxiety symptoms, as well as quality of life, in patients with TRD. This study provides evidence supporting the use of Toludesvenlafaxine as an effective treatment option for TRD and emphasizes the need for further research to confirm its long-term efficacy and safety."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia (clinicaltrials.gov) - P=N/A | N=384 | Recruiting | Sponsor: Beijing Tiantan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Fibromyalgia • Musculoskeletal Pain • Pain • Rheumatology

The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia (clinicaltrials.gov) - P=N/A | N=384 | Recruiting | Sponsor: Beijing Tiantan Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Fibromyalgia • Musculoskeletal Pain • Pain • Rheumatology

Occurrence and seasonal variation of contaminants of emerging concern (CECs) in influent and effluent of four Australian wastewater treatment plants (WWTPs). (PubMed, Chemosphere) - "Spatial and seasonal variations were evident; analgesics (codeine) and antibiotics (ofloxacin, sulfamethoxazole, trimethoprim) were higher in autumn, while psychiatric drugs (citalopram, desvenlafaxine) and DEET peaked in spring...Risk Quotient assessment indicated low acute risks to algae and invertebrates, but moderate to high chronic risks to fish from venlafaxine, fluoxetine, citalopram, and carbamazepine (90th percentile)...Invertebrates faced moderate chronic risks from acetaminophen and sulfamethoxazole. This assessment did not account for dilution in receiving waters and considered both peak and typical exposure levels."

Journal • Pain • Psychiatry

Real-World Utilization and Prescribing Impact of Psychiatric Pharmacogenomic Testing in Youth (AACAP 2025) - "Among 318 youth with longitudinal pre- and posttesting data, prescribing for desvenlafaxine, duloxetine, and venlafaxine were significantly increased after PGx testing (all false discovery rate (FDR)-adjusted p < .01). Psychiatric PGx testing in youth showed strong potential for clinical impact, with 1 in 6 youth having a mental health medication DGI at the time of testing. PGx testing significantly increased SNRI antidepressant prescribing. The greatest increase was observed with desvenlafaxine, which is not currently approved by the FDA for use in youth."

Biomarker • Clinical • Real-world • Real-world evidence • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Immunology • Mood Disorders • Psychiatry

Antidepressants and Microscopic Colitis: A Propensity-Matched Comparison to Bupropion (ACG 2025) - "Other individual agents, including sertraline, fluoxetine, venlafaxine, and desvenlafaxine, were not significantly associated with MC compared to bupropion. After propensity score matching, ten antidepressant exposure groups (including SSRIs and SNRIs) were compared to bupropion for the development of microscopic colitis. Both SSRIs and SNRIs as medication classes were associated with significantly lower odds of developing microscopic colitis compared to bupropion (SSRI OR 0.68, 95% CI 0.54–0.86, p = 0.001; SNRI OR 0.64, 95% CI 0.50–0.81, p = 0.0002). Among individual agents, duloxetine (OR 0.79, 95% CI 0.45–0.77, p < 0.0001), escitalopram (OR 0.77, 95% CI 0.60–0.98, p = 0.04), and paroxetine (OR 0.66, 95% CI 0.45–0.97, p = 0.03) were also significantly associated with decreased odds."

Gastroenterology • Gastrointestinal Disorder • Immunology

Inner ear signs and symptoms induced by antidepressants: a disproportionality analysis based on the FAERS database. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The results suggest a significant association between antidepressants- such as duloxetine, paroxetine, bupropion, venlafaxine, sertraline, desvenlafaxine, escitalopram, and citalopram- and inner ear signs and symptoms. These symptoms may severely impact patients' quality of life and daily functioning, highlighting the need for clinicians to closely monitor patients for inner ear signs and symptoms when prescribing these medications."

Journal • Ataxia • Movement Disorders • Otorhinolaryngology • Vertigo

The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis. (PubMed, Lancet) - "We found strong evidence that antidepressants differ markedly in their physiological effects, particularly for cardiometabolic parameters. Treatment guidelines should be updated to reflect differences in physiological risk, but choice of antidepressant should be made on an individual basis, considering clinical presentation and preferences of patients, carers, and clinicians."

Journal • Retrospective data • CNS Disorders • Mental Retardation • Metabolic Disorders • Psychiatry

Side effect profile and comparative tolerability of newer generation antidepressants in the acute treatment of major depressive disorder in children and adolescents: protocol for a systematic review and network meta-analysis. (PubMed, BMJ Open) - "The following antidepressants will be considered: agomelatine, alaproclate, bupropion, citalopram, desvenlafaxine, duloxetine, edivoxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, venlafaxine, vilazodone and vortioxetine. The findings will be published in a peer-reviewed journal and may be presented at international conferences. CRD420251011399."

Adverse events • Journal • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry • Suicidal Ideation

Beyond mood: a systematic review and network meta-analysis of the physiological and cardiometabolic effects of antidepressants (ECNP 2025) - "Clinically meaningful differences included approximately 4 kg variation in weight change, with significant weight loss observed for agomelatine and marked weight gain for maprotiline. Cardiovascular effects varied notably; nortriptyline increased heart rate by over 21 bpm relative to fluvoxamine, which decreased it...While paroxetine, duloxetine, desvenlafaxine, and venlafaxine decreased body weight, they significantly raised total cholesterol levels, with duloxetine additionally elevating glucose. Liver enzyme elevations were consistently observed with duloxetine, desvenlafaxine, and levomilnacipran, though these were not deemed clinically significant...Healthcare organisations recommend that consideration and discussion of potential side effects should form an integral part of the antidepressant prescribing process (3). Incorporating these differential physiological risks into clinical guidelines can support tailored prescribing decisions, balancing psychiatric..."

Retrospective data • Review • Bipolar Disorder • CNS Disorders • Depression • General Anxiety Disorder • Major Depressive Disorder • Mental Retardation • Mood Disorders • Musculoskeletal Pain • Obsessive-Compulsive Disorder • Post-traumatic Stress Disorder • Psychiatry • Schizophrenia

Redressing long-term antidepressant use in general practice (RELEASE) (ECNP 2025) - "Antidepressants include selective serotonin reuptake inhibitors (sertraline, escitalopram fluoxetine, paroxetine, fluvoxamine and citalopram); serotonin and norepinephrine reuptake inhibitors (venlafaxine, desvenlafaxine, duloxetine); and other antidepressants (mirtazapine, vortioxetine, mianserin, moclobemide, reboxetine, agomelatine). 26 practices and 485 participants randomised. Data collection complete November 2025. Implications: This study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of the RELEASE multi-strategy intervention in prompting review of antidepressant medication and supporting informed decision-making and safe cessation via hyperbolic tapering to minimise withdrawal symptoms to improve primary mental health care and outcomes for patients."

Alzheimer's Disease • CNS Disorders • Dementia • Mood Disorders • Neuralgia • Psychiatry

The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia (clinicaltrials.gov) - P=N/A | N=384 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital

Monotherapy • New trial • Fibromyalgia • Musculoskeletal Pain • Pain • Rheumatology

THE PHYSIOLOGICAL AND CARDIOMETABOLIC EFFECTS OF ANTIDEPRESSANTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (WPA-WCP 2025) - "Clinically meaningful differences included approximately 4kg variation in weight change, with significant weight loss observed for agomelatine and weight gain for maprotiline. Nortriptyline increased heart rate by over 21 bpm relative to fluvoxamine, which decreased it...While paroxetine, duloxetine, desvenlafaxine, and venlafaxine decreased body weight, they significantly raised total cholesterol levels, with duloxetine additionally elevating glucose...Conclusions Our findings highlight clinically relevant variations in adverse effects across antidepressants, particularly cardiometabolic parameters. Incorporating these physiological risks into practice can support tailored prescribing decisions, balancing psychiatric efficacy with patient-specific physical health considerations and preferences."

Retrospective data • Review • CNS Disorders • Mental Retardation • Psychiatry

OPTION-VMS: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats (clinicaltrials.gov) - P=N/A | N=998 | Active, not recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Trial completion date: Nov 2026 ➔ May 2026 | Trial primary completion date: Feb 2026 ➔ Aug 2025

Real-world evidence • Trial completion date • Trial primary completion date

Visual Snow Syndrome: A Case Report and Literature Review (IHC 2025) - "He was treated with paroxetine, pregabalin, valproate, and gabapentin with symptom remission...Lamotrigine was started in 2024, but was ineffective; lacetazolamide at 500 mg caused paresthesias.Given the persistence of symptoms, the patient underwent a psychiatric evaluation, which suggested a comorbid mood disorder, leading to the initiation of treatment with desvenlafaxine.Despite multiple interventions, VSS symptoms persisted, reinforcing the hypothesis of cortical hyperexcitability and altered thalamocortical dynamics as underlying mechanisms. Studies have suggested that hypermetabolism in the lingual gyrus and dysfunction in the extrastriate visual cortex may contribute to the pathophysiology of VSS Conclusion The diagnosis of vasoconstriction syndrome(VCS) and its clinical overlap with migraine is complex. Its lack of improvement with multiple pharmacological approaches underscores the need for targeted therapies, consistent with previous studies showing variable..."

Case report • Clinical • Review • CNS Disorders • Migraine

The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia (clinicaltrials.gov) - P=N/A | N=384 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital

Monotherapy • New trial • Fibromyalgia • Musculoskeletal Pain • Pain • Rheumatology

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-Release Tablets on Somatic Symptoms of Major Depressive Disorder: A Prospective, Single-Arm, Multicenter Clinical Study (WFSBP 2025) - "Toludesvenlafaxine hydrochloride significantly improved somatic symptoms in patients with MDD and somatic symptoms, with a favorable safety profile, supporting its use as an effective treatment option."

Clinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Effect of a Novel Antidepressant and Anticancer Nuc01 on Depression in Cancer Survivors. (PubMed, Curr Issues Mol Biol) - "Depression in cancer survivors is commonly treated with serotonin and norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine...These findings suggest that Nuc01 may function as an LSD1 inhibitor with potential anticancer properties. Collectively, the data indicate that Nuc01 appears to exhibit dual functional characteristics: acting as a triple reuptake inhibitor potentially applicable for depression treatment and as an LSD1 inhibitor demonstrating anticancer potential."

Journal • CNS Disorders • Depression • Mood Disorders • Oncology • Psychiatry

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-Release Tablets on Somatic Symptoms of Major Depressive Disorder: A Prospective, Single-Arm, Multicenter Clinical Study. (PubMed, Neuropsychiatr Dis Treat) - P4 | "Toludesvenlafaxine hydrochloride significantly improved somatic symptoms in patients with MDD and somatic symptoms, with a favorable safety profile, supporting its use as an effective treatment option. NCT05849272."

Clinical • Journal • CNS Disorders • Depression • Fatigue • Major Depressive Disorder • Mood Disorders • Pain • Psychiatry

A Study on the Efficacy and Safety of Toludesvenlafaxine Hydrochloride in the Treatment of Major Depressive Disorder in Adolescents Aged 13-17 Years (ChiCTR) - P4 | N=120 | Not yet recruiting | Sponsor: Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer

New P4 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Factors associated with initial medication adherence with first-line therapy for depression. (PubMed, J Affect Disord) - "About 61 % of the MDD patients had optimal IMA with significant variation in IMA across antidepressant agents, in addition to other patients' characteristics. Findings highlight the importance of IMA and the need for targeted interventions to achieve optimal IMA."

Journal • Back Pain • Cardiovascular • CNS Disorders • Crohn's disease • Depression • Dermatology • Dyslipidemia • Gastroenterology • Genetic Disorders • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Major Depressive Disorder • Mood Disorders • Obesity • Psoriasis • Psoriatic Arthritis • Psychiatry • Rheumatology

Duloxetine inhibits breast cancer progression by suppressing AKT signaling and inducing Bax/Bcl-2-mediated apoptosis. (PubMed, Med Oncol) - "This study systematically evaluated the anti-tumor efficacy of six clinically used antidepressants (escitalopram, amitriptyline, fluoxetine, paroxetine, desvenlafaxine, and duloxetine) in 4T1 (murine triple negative) and MCF-7 (human ER+/HER2-) breast cancer cells...Although less potent than docetaxel, duloxetine still exhibited significant anti-proliferative, anti-migratory, and pro-apoptotic effects...Additionally, duloxetine promotes apoptosis by upregulating Bax and downregulating Bcl-2 expression both in vitro and in vivo. These findings reveal that duloxetine exerts anti-breast cancer effects through inhibiting AKT/mTOR signaling and promoting Bax/Bcl-2-mediated apoptosis, highlighting its potential for therapeutic repurposing as an adjunct treatment-particularly, in breast cancer patients with coexisting depression."

IO biomarker • Journal • Breast Cancer • CNS Disorders • Depression • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Psychiatry • Solid Tumor • Triple Negative Breast Cancer • BCL2 • CDH1 • ER • HER-2

OPTION-VMS: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats (clinicaltrials.gov) - P=N/A | N=1003 | Active, not recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Real-world evidence